Galapagos NV and Gilead Sciences closed a global license and collaboration agreement for the global development and commercialization of filgotinib in inflammatory diseases, establishing an upfront license fee payment of $300 million by Gilead to Galapagos. Gilead also made a $425 million equity investment in Galapagos.

Under the terms of the agreement, the companies will collaborate jointly on the global development of filgotinib starting with the initiation of Phase 3 trials in rheumatoid arthritis (RA). Galapagos will co-fund 20% of global development activities and Gilead will be responsible for manufacturing and worldwide marketing and sales activities. Galapagos mantained the option to co-promote filgotinib in the UK, Germany, France, Italy, Spain, Belgium, the Netherlands and Luxembourg, in which case the companies will share profits equally.


Please enter your comment!
Please enter your name here